Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 3,181–3,190 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 3181

    Medicine slug
    flibanserin
    Medicine name
    Flibanserin
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    10
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitor (Ketoconazole) In a study of 24 healthy female subjects, ketoconazole 400 mg administered once daily for 5 days following a light breakfast increased flibanserin 50 mg single-dose exposure (AUC 0-inf ) 4.5-fold and Cmax 1.8-fold compared to flibanserin 50 mg alone [ see Warnings and Precautions (5.2) , Adverse Reactions (6.1) and Drug Interactions (7) ] .
    3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitor (Itraconazole) In a study of 12 healthy male and female subjects, itraconazole 200 mg administered once daily for 4 days following a loading dose of 400 mg increased flibanserin 50 mg single dose exposure (AUC 0-inf ) 2.6-fold and Cmax 1.7-fold when flibanserin was given 2 hours after itraconazole on Day 5, compared to exposures with flibanserin 50 mg alone.
    4. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitor (Grapefruit Juice) In a study of 26 healthy female subjects, grapefruit juice (240 mL) increased flibanserin 100 mg single dose exposure (AUC 0-inf ) by 1.4-fold and Cmax 1.1-fold compared to flibanserin 100 mg alone [see Warnings and Precautions (5.2) , Adverse Reactions (6.1) and Drug Interactions (7) ] .
    5. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Weak CYP3A4 Inhibitor (Oral Contraceptives) In a meta-analysis of 17 oral contraceptive users and 91 non-users in Phase 1 studies, the oral contraceptive users had a 1.4-fold higher flibanserin AUC and 1.3‑fold higher Cmax compared to the non-users [see Adverse Reactions (6.1) and Drug Interactions (7) ] .
    6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
    7. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitor (Ketoconazole) In a study of 24 healthy female subjects, ketoconazole 400 mg administered once daily for 5 days following a light breakfast increased flibanserin 50 mg single-dose exposure (AUC 0-inf ) 4.5-fold and Cmax 1.8-fold compared to flibanserin 50 mg alone [ see Warnings and Precautions (5.2) , Adverse Reactions (6.1) and Drug Interactions (7) ] .
    8. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitor (Itraconazole) In a study of 12 healthy male and female subjects, itraconazole 200 mg administered once daily for 4 days following a loading dose of 400 mg increased flibanserin 50 mg single dose exposure (AUC 0-inf ) 2.6-fold and Cmax 1.7-fold when flibanserin was given 2 hours after itraconazole on Day 5, compared to exposures with flibanserin 50 mg alone.
    9. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitor (Grapefruit Juice) In a study of 26 healthy female subjects, grapefruit juice (240 mL) increased flibanserin 100 mg single dose exposure (AUC 0-inf ) by 1.4-fold and Cmax 1.1-fold compared to flibanserin 100 mg alone [see Warnings and Precautions (5.2) , Adverse Reactions (6.1) and Drug Interactions (7) ] .
    10. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Weak CYP3A4 Inhibitor (Oral Contraceptives) In a meta-analysis of 17 oral contraceptive users and 91 non-users in Phase 1 studies, the oral contraceptive users had a 1.4-fold higher flibanserin AUC and 1.3‑fold higher Cmax compared to the non-users [see Adverse Reactions (6.1) and Drug Interactions (7) ] .
    11. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      The 200 mg itraconazole dose does not maximally inhibit the CYP3A4 enzyme [see Drug Interactions (7) ].
    12. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      The 200 mg itraconazole dose does not maximally inhibit the CYP3A4 enzyme [see Drug Interactions (7) ].

  2. Projected row 3182

    Medicine slug
    flibanserin
    Medicine name
    Flibanserin
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Drugs Metabolized by CYP3A4 (Simvastatin) An open-label, randomized, crossover study in 12 healthy men and women evaluated the effect of flibanserin 50 mg twice daily for 4 days on the pharmacokinetics of simvastatin 40 mg once daily.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Drugs Metabolized by CYP3A4 (Simvastatin) An open-label, randomized, crossover study in 12 healthy men and women evaluated the effect of flibanserin 50 mg twice daily for 4 days on the pharmacokinetics of simvastatin 40 mg once daily.

  3. Projected row 3183

    Medicine slug
    flibanserin
    Medicine name
    Flibanserin
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Flibanserin increased the AUC 0-inf of simvastatin, a substrate of CYP3A4, 1.3‑fold and Cmax by 1.2-fold.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Flibanserin increased the AUC 0-inf of simvastatin, a substrate of CYP3A4, 1.3‑fold and Cmax by 1.2-fold.

  4. Projected row 3184

    Medicine slug
    flibanserin
    Medicine name
    Flibanserin
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Digoxin and P-glycoprotein Substrates A single center, open-label, randomized, two-way crossover study in 24 healthy men and women evaluated the effect of flibanserin on the pharmacokinetics of digoxin.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Digoxin and P-glycoprotein Substrates A single center, open-label, randomized, two-way crossover study in 24 healthy men and women evaluated the effect of flibanserin on the pharmacokinetics of digoxin.

  5. Projected row 3185

    Medicine slug
    flibanserin
    Medicine name
    Flibanserin
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Flibanserin 100 mg was administered once daily over 5 days followed by a single dose of 0.5 mg digoxin, a P-gp substrate.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)

      Flibanserin label

      Version not recorded · Effective date not recorded

      Flibanserin 100 mg was administered once daily over 5 days followed by a single dose of 0.5 mg digoxin, a P-gp substrate.

  6. Projected row 3186

    Medicine slug
    florbetaben-f-18
    Medicine name
    Florbetaben F-18
    Enzyme or transporter
    CYP2J2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    1
    Complete sentence records
    1. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b0915068-cfd4-4d72-b9f8-7e31fe83cd1e (opens source in a new tab)

      Florbetaben F-18 label

      Version not recorded · Effective date not recorded

      In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2.

  7. Projected row 3187

    Medicine slug
    florbetaben-f-18
    Medicine name
    Florbetaben F-18
    Enzyme or transporter
    CYP4F2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    1
    Complete sentence records
    1. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b0915068-cfd4-4d72-b9f8-7e31fe83cd1e (opens source in a new tab)

      Florbetaben F-18 label

      Version not recorded · Effective date not recorded

      In vitro studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2.

  8. Projected row 3188

    Medicine slug
    fluconazole
    Medicine name
    Fluconazole
    Enzyme or transporter
    CYP2C9
    Role
    INHIBITOR
    Asserted sentences
    1
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:afde17e7-b95b-4cd5-97eb-e361724014bd (opens source in a new tab)

      Fluconazole label

      Version not recorded · Effective date not recorded

      (See PRECAUTIONS . ) Abrocitinib : When coadministered with fluconazole (inhibitor of CYP2C9, 2C19, and 3A4), the systemic exposure (AUC) of abrocitinib was approximately 4.8-fold higher and the combined exposure (AUC) of abrocitinib and its active metabolites was approximately 2.5-fold higher compared to when abrocitinib was administered alone (See PRECAUTIONS ).

  9. Projected row 3189

    Medicine slug
    fluconazole
    Medicine name
    Fluconazole
    Enzyme or transporter
    CYP2C9
    Role
    SUBSTRATE
    Asserted sentences
    1
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:afde17e7-b95b-4cd5-97eb-e361724014bd (opens source in a new tab)

      Fluconazole label

      Version not recorded · Effective date not recorded

      Voriconazole: Voriconazole is a substrate for both CYP2C9 and CYP3A4 isoenzymes.

  10. Projected row 3190

    Medicine slug
    fluconazole
    Medicine name
    Fluconazole
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    1
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:afde17e7-b95b-4cd5-97eb-e361724014bd (opens source in a new tab)

      Fluconazole label

      Version not recorded · Effective date not recorded

      Voriconazole: Voriconazole is a substrate for both CYP2C9 and CYP3A4 isoenzymes.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=3180

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy